Page last updated: 2024-09-04

pomalidomide and Central Nervous System Neoplasms

pomalidomide has been researched along with Central Nervous System Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Nohgawa, M; Oka, S; Ono, K1
Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE1
Batchelor, TT; Grommes, C; Nayak, L; Tun, HW1
Babusis, D; Copland, JA; Edenfield, B; Huang, P; Katz, J; Li, Z; Moghaddam, MF; Personett, D; Qiu, Y; Shirely, MA; Tang, Y; Tun, HW1
Dalto, S; Montefusco, V; Mussetti, A1
Gertz, MA1

Reviews

1 review(s) available for pomalidomide and Central Nervous System Neoplasms

ArticleYear
Introduction of novel agents in the treatment of primary CNS lymphoma.
    Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape

2019

Trials

1 trial(s) available for pomalidomide and Central Nervous System Neoplasms

ArticleYear
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
    Blood, 2018, 11-22, Volume: 132, Issue:21

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dexamethasone; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retinal Neoplasms; Thalidomide; Treatment Outcome

2018

Other Studies

4 other study(ies) available for pomalidomide and Central Nervous System Neoplasms

ArticleYear
Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Dexamethasone; Female; Humans; Injections, Spinal; Plasmacytoma; Renal Dialysis; Thalidomide; Treatment Outcome

2020
Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Central Nervous System Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma; Male; Mice; Mice, Nude; Rats; Thalidomide; Tumor Microenvironment; U937 Cells

2013
Effective treatment of pomalidomide in central nervous system myelomatosis.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome

2013
Pomalidomide and myeloma meningitis.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Multiple Myeloma; Thalidomide

2013